Réunion

Reimbursed Care Access

Réunion, as an overseas department of France, is subject to French national drug law and health regulation. Medical access is available in restricted form for esketamine (SPRAVATO) under the French reimbursement/coverage framework and for ketamine as an established anesthetic and as off‑label psychiatric use in hospital settings; all classic psychedelic compounds (psilocybin, MDMA for non‑trial clinical use, DMT, 5‑MeO‑DMT, ibogaine, mescaline, ayahuasca and 2C‑X series) are controlled under French ‘stupéfiants’ law and have no routine reimbursed medical pathway outside authorised clinical research.